title: The effect of nifedipine, a calcium channel blocker, on liver ischemia in dogs.
abstract: This study was undertaken in order to determine whether the administration of nifedipine, a calcium channel blocker, could protect the liver from ischemic damage and to investigate its effect on the hepatic cellular energy status and cardio-vascular system after 60 minutes of hepatic ischemia in dogs. The ischemia was induced by temporarily clamping the portal vein and hepatic artery. One group of animals (n = 17) received nifedipine (5 micrograms/kg body weight) intravenously 15 minutes before the induction of liver ischemia, which was continued at a dose of 0.2 microgram/kg body weight/min throughout the ischemic period, and for an additional 30 minutes afterwards. Control dogs (n = 16) were not given nifedipine and survival was observed over seven days. The survival rate was 83 per cent in the nifedipine treated animals and 0 per cent in the control animals. Serum glutamic oxaloacetic transaminase levels were greatly increased following ischemia, and they were significantly lowered with the nifedipine treatment. The hepatic energy charge decreased remarkably during the hepatic ischemia, however it increased gradually after declamping but did not returned to its preoperative value in either group until one hour later and then it was higher in the nifedipine treated animals than in the control animals. Cardiac index and portal venous blood flow ratio remained higher in the nifedipine treated animals than in the control animals, after the ischemic period. These results suggest that nifedipine may have a powerful cytoprotective effect and that the period of warm hepatic ischemia could be prolonged with its use.
authors.affiliation: Surgical Department, Faculty of Medicine, University of Tokyo, Japan.
authors.forename: F
authors.initials: F
authors.lastname: Yoshimi
authors.forename: M
authors.initials: M
authors.lastname: Ishimaru
authors.forename: M
authors.initials: M
authors.lastname: Sodeyama
authors.forename: T
authors.initials: T
authors.lastname: Nagao
authors.forename: N
authors.initials: N
authors.lastname: Kawano
authors.forename: Y
authors.initials: Y
authors.lastname: Morioka
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D004285:Dogs; D007275:Injections, Intravenous; D007511:Ischemia / Q000097:blood / Q000188:drug therapy*; D008099:Liver / Q000098:blood supply* / Q000473:pathology; D008115:Liver Regeneration / Q000187:drug effects; D009336:Necrosis; D009543:Nifedipine / Q000627:therapeutic use*
chemical_list: D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D009543:Nifedipine